Download PDF
Semin Thromb Hemost 2013; 39(08): 973
DOI: 10.1055/s-0033-1358798
Erratum
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats

Giovanni Di Minno
1   Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Napoli, Italy
,
Mariana Canaro
2   Department of Hemostasis and Thrombosis, Son Espases Universitary Hospital, Palma de Mallorca, Spain
,
James W. Ironside
3   National Creutzfeldt-Jakob Disease Surveillance Unit, School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom
,
David Navarro
4   Department of Microbiology, Microbiology Service, Hospital Clínico Universitario, School of Medicine, University of Valencia, Valencia, Spain
,
Carlo F. Perno
5   Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
,
Andreas Tiede
6   Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
,
Lutz Guertler
7   Max von Pettenkofer Institute for Hygiene and Medical Microbiology, University of München, Munich, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
20 October 2013 (online)

    Permissions and Reprints

Correction to:

Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving ThreatsSemin Thromb Hemost 2013; 39(07): 779-793
DOI: 10.1055/s-0033-1354420

The authors regret mentioning potential misinformation for few products in Tables 2 and 3 of the above article (Volume 39, Number 7, pp. 782–786). The complete details and updates are summarized below:

Page No.

Column head

Row

Potential misinformation

Corrected information

Table 2

783

Potential risks

Kogenate FS (Bayer)

Allergic type hypersensitivity reactions; risk of infection from unknown/emerging viral/other pathogens; risk of thrombotic events; formation of neutralizing antibodies; thrombophlebitis/thrombosis at infusion/catheter site

Allergic type hypersensitivity reactions; risk of thrombotic events; formation of neutralizing antibodies; thrombophlebitis/thrombosis at infusion/catheter site

784

Potential risks

Xyntha/ReFacto AF (Pfizer)

Allergic type hypersensitivity reactions; risk of infection from unknown/emerging viral/other pathogens; formation of neutralizing antibodies; lack of effect (bleeding events)

Allergic type hypersensitivity reactions; formation of neutralizing antibodies; lack of effect (bleeding events)

Table 3

786

Purification

BeneFIX (Pfizer)

Immunoaffinity chromatography

Affinity chromatography